Next, we constructed an intracranial GBM PDX model in nude mice, which exhibited that tumors in the TBD0220-KRAS group grew at faster rates, conferring a relatively shorter survival time, while the tumors in the TBD0220-KRAS+ERBIN and the TBD0220-KRAS+EPIC groups presented retarded growth. This evidence concerns the gene KRAS and glioblastoma.